Albumedix is attending Cell & Gene Meeting on the Mesa 2023. 10th - 12th October 2023

Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has successfully closed the acquisition of Albumedix Ltd. as of September 30, 2022.

Billie is a Research Scientist within Albumedix and a glowing example of our many bright minds behind the vial. Almost completing her third year working for the company, the subsequent discussion will take you through Billie's previous experience and her role within the Albumedix team. Albumedix is a recognized leader of best-in-class albumin-enabled solutions, and our Technology Centre is a vital part of our business. See what Billie has to say about her day-to-day duties in the Technical Group and see what fantastic advice she has for you!

Sartorius to acquire Albumedix, creating a powerhouse for innovative advanced therapy solutions

Highlighting the manufacture and distribution of albumin, a biological product that is helping to address critical issues in the development, production and formulation of life-saving vaccines.

PRESS RELEASE: Valneva’s inactivated COVID-19 vaccine, VLA2001, including Albumedix´ Recombinant Human Albumin (rHA) as an essential component, received regulatory approval from MHRA on April 14th. This marks an expansion of the companies’ existing collaboration and further validates the use of Albumedix Recombumin® rHA products in the manufacturing process and final formulation of critical vaccines.

Has COVID-19 revolutionizedthe future of regulation of medicine development and authorization or are we simply responding to an unprecedented global pandemic? Our Head of Regulatory Affairs and Enhanced Services, Harriet Edwards, delves deep on how the pademic changed the industry we work in today.

PRESS RELEASE: Nottingham, UK, 1 September 2021 – Albumedix Ltd. (‘Albumedix’), a globally recognized leader in albumin-based enabling solutions for advanced therapies and next-generation biopharmaceuticals, announced today the appointment of Joanna Hay as Vice President of Commercial Operations, effective as of September 1st, 2021.

Surface engineering is key for medical devices, particularly the ones that interact with the human body like tubing, catheters, and stents which need to be implanted. It is essential to have strong control on the performance of the coatings, so that everyone is assured that they are uniformly present on the surfaces, that the coatings allow an effective flow of body fluids (such as blood), and that they promote a long lifespan not diminishing or reducing the effectiveness of the medical device in use1 - all of the above, according to the regulation standards, are required to be met by oversight groups.

Did you know that unlike other recombinant human albumin manufacturers, Albumedix are so much more than simply ‘an albumin supplier’? When you work with us, you also get access to 100 brilliant minds behind the vial, including a dedicated Business Development Director responsible for managing your account.

Meet Dangerous Dave Phillipson; a formidable, Nottingham based, three-time Paralympian in tennis who took to the water in 2017 and is now paracanoeing his way to Tokyo 2021.

Meet Helen Rawsthorne. Helen is a Senior Research Scientist within Albumedix and a truly brilliant example of our many brilliant minds. Presently in her 7th year working for the company, the following interview will take you through Helen's background, her role within Albumedix and give you a sneak preview into what our Technical Group get up to in the day.

Albumedix are thrilled to be able to continue supporting the Nottinghamshire Wildlife Trust in their endeavours to protect and restore the beautiful environment and wildlife both on our doorstep and across the region.

Albumedix is a world leading manufacturer of recombinant human albumin (rHA), and as such our manufacturing plant is the core of our business. As a company, we talk a lot about our rHA products, how they’re useful in different applications and what benefits they can bring to final therapies for patients worldwide. However, we don’t talk as much about the amazing people within our business that make the magic happen.

In December, Albumedix held a 'Capping off Ceremony' to celebrate the brand new, four-storey manufacturing plant extension being confirmed as watertight!